Pure Global
NCT05932901

OPTIMISE-CKD Drug Utilization

A Multinational, Observational, Secondary Data Study Describing Management and Treatment With Dapagliflozin in Routine Clinical Practice Among Patients With Chronic Kidney Disease
AstraZeneca·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Disease
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
Minnesota,Kyoto City,Tokyo, Japan,United States of America
Timeline & enrollment
Phase
N/A
Start date
May 04, 2022
End date
Aug 31, 2023
Enrollment
79432108 participants
Primary outcome

Baseline demographics,Baseline clinical characteristics,Baseline comedications,Baseline eGFR in ml/min/1.73m2,Baseline uACR in mg/g,Baseline serum creatinine in mg/dl,Baseline calcium in mg/dl,Baseline sodium in mmol/L,Baseline hemoglobin A1c in %,Baseline hematocrit in %,Baseline systolic blood pressure in mmHg

Summary

This is a multi-national, observational study program using secondary data sources to address
 research questions related to 1) real-world dapagliflozin utilisation in CKD and potential
 for further utilisation, 2), the current CKD treatment landscape and 3) real-world
 effectiveness of dapagliflozin in CKD (pending feasibility assessment).

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05932901
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05932901 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 79432108 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.